FDA Approves Revumenib for Relapsed or Refractory Acute Leukaemia with a KMT2A Translocation By Ogkologos - December 10, 2024 752 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the AUGMENT-101 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Adopts a Positive Opinion for a New Route of Administration Together with a New Pharmaceutical Form and a New Strength for Isatuximab National Study Examines Genetic Testing to Inform Follow-up Care for Cancer Survivors Taletrectinib Demonstrates Durable Long-Term Efficacy in Both TKI-naïve and Crizotinib-pretreated Patients with Advanced ROS1-positive NSCLC MOST POPULAR How serendipity sent this oncologist in search of a cure for... August 12, 2022 EMA Adopts a Positive Opinion for a New Route of Administration... May 8, 2026 Trastuzumab Deruxtecan Prolongs PFS After Endocrine-Based Therapy in Patients with HR-positive,... October 17, 2024 Spirituality Resources December 9, 2020 Load more HOT NEWS Five Questions With…Amber. A New Study Suggests Screen Time Might Not Be The Worst... Cern και αντιμετώπιση του καρκίνου Addressing Disparities and Raising Awareness During National Black Family Cancer Awareness...
